Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Capex-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Paradigm Biopharmaceuticals's Capital Expenditure for the six months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Paradigm Biopharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Capex-to-Revenue Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Capex-to-Revenue

Get a 7-Day Free Trial

1.50

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Paradigm Biopharmaceuticals's Capex-to-Revenue

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Capex-to-Revenue falls into.

Paradigm Biopharmaceuticals Capex-to-Revenue Calculation

Paradigm Biopharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0.032
	=	0.00

Paradigm Biopharmaceuticals's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Paradigm Biopharmaceuticals (OTCPK:PBIGF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Paradigm Biopharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).